NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.
Source: onclive.com